We hypothesized that tirzepatide can improve morbidity and mortality in adults with obesity or overweight but without diabetes.
We will cover the prevalence, diagnosis, treatment, and management of obesity, along with related cardiometabolic disorders.
Obesity and Cardiometabolic Disease Read More »
In the first part of our two-part panel discussion, listen to our guest speaker Prof. Mei-Yueh Lee discussing guideline recommendations for weight reduction goals. She covers the AGA 2022 Guideline and reviews the NICE 2025 Guideline Recommendations and provides an update on the status of several pharmacological treatment options, including orlistat, semaglutide, naltrexone/bupropion, liraglutide, and tirzepatide.
Review Guidelines for Obesity: Explore Pharmacological Treatment Options Read More »
This study aims to determine real-world titration, persistence and effectiveness of GLP1RAs in patients managed within a multidisciplinary obesity clinic.
Welcome to our case study video featuring Prof. Scott Issacs, where we delve into the management of a complex case involving a 56-year-old patient with a seven-year history of type 2 diabetes, initially preceded by prediabetes.
Dr. Scott Issacs Case Study Read More »
In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes.
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial Read More »
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity Read More »
Central to the ACC’s strategic plan is the generation of actionable knowledge—a concept that places emphasis on making clinical information easier to consume, share, integrate, and update. To this end, the ACC has shifted from developing isolated documents to creating integrated “solution sets.”
We aimed to investigate the safety, tolerability, pharmacokinetic properties, and pharmacodynamic effects of single ascending doses (part A) and multiple ascending doses (parts B and C/D) of amycretin in adult participants with overweight or obesity.
Our objective was to model the potential cost-effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.
This site is only for use by healthcare professionals.
By continuing to view this site you are confirming that you are a healthcare professional.
